RELATED STUDY
In vivo characterization of the highly selective monoacylglycerol lipase inhibitor KML29: antinociceptive activity without cannabimimetic side effects
Key Findings: The selective MAGL inhibitor, KML29, significantly reduced inflammation and swelling in this mouse model of neuropathic and inflammatory pain and protected gastric tissue. It did not appear to have any unpleasant cannabimimetic side effects and may present a therapeutic adjunct target to neuropathic pain management without the risks presented by NSAIDS.
Type of Study: Animal Study
Study Result: Positive
Study Location(s): United States
Year of Pub: 2014
Cannabinoids Studied: Tetrahydrocannabinol (THC), AM-x Synthetic Cannabinoids, SR-x Synthetic Cannabinoids, Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL), Synthetic Cannabinoid (unspecified), Palmitoylethanolamide (PEA)
Phytocannabinoid Source: Not Applicable
Receptors Studied: CB1, CB2, CB1 agonist, CB1 antagonist, CB2 antagonist
